Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brain metastases.

M G Ewend1, L A Carey, D E Morris

  • 1Division of Neurosurgery, University of North Carolina at Chapel Hill, 148 Burnett-Womack Building, Campus Box 7060, Chapel Hill, NC 27599-7060, USA. ewend@med.unc.edu

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

ESMO open·2026
Same author

Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.

ESMO open·2026
Same author

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

ESMO open·2025
Same author

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

ESMO open·2025
Same author

HER2DX genomic test in early-stage HER2-positive breast cancer.

ESMO open·2024

Brain metastases are a growing concern in cancer patients. Tailoring treatments to individual tumor types, rather than using a single approach, is crucial for improving survival and managing these challenging secondary cancers.

Area of Science:

  • Neuro-oncology
  • Medical oncology
  • Radiation oncology

Background:

  • Brain metastases significantly increase morbidity and mortality in patients with systemic cancers.
  • Current systemic cancer therapies often fail to penetrate the central nervous system (CNS), leaving patients vulnerable to brain metastasis development.
  • Established treatments like surgery, radiosurgery, and radiation therapy are utilized, but a multimodal approach is often optimal.

Purpose of the Study:

  • To emphasize the need for individualized treatment strategies for brain metastases.
  • To highlight the limitations of current systemic therapies in penetrating the CNS and overcoming tumor resistance.
  • To advocate for tailored treatment algorithms based on specific tumor biology and sensitivities.

Main Methods:

Related Experiment Videos

  • Review of current treatment modalities for brain metastases, including surgery, radiosurgery, and radiation therapy.
  • Discussion of the challenges posed by the blood-brain barrier (BBB) to systemic chemotherapy delivery.
  • Analysis of tumor-specific characteristics, including chemotherapy and radiotherapy sensitivity and underlying biology.

    • Main Results:

    • Systemic chemotherapy has a limited role due to BBB penetration issues and inherent tumor resistance.
    • A one-size-fits-all treatment algorithm for brain metastases is suboptimal.
    • Individualized treatment strategies considering tumor origin, biology, and sensitivity are essential for effective management.

    Conclusions:

    • Treatment of brain metastases requires a personalized approach, moving beyond traditional, generalized algorithms.
    • Recognizing the unique biological and sensitivity profiles of different tumor types is key to optimizing patient outcomes.
    • Multimodal therapeutic strategies, tailored to specific brain metastases, are critical for improving survival and reducing morbidity.